Get the Stockscreener App
0.8899
4.14%
-0.0384
After Hours:
.87
-0.0199
-2.24%
Renovorx Inc stock is traded at $0.8899, with a volume of 285.67K.
It is down -4.14% in the last 24 hours and down -4.51% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.9283
Open:
$0.9226
24h Volume:
285.67K
Relative Volume:
0.88
Market Cap:
$40.09M
Revenue:
$1.12M
Net Income/Loss:
$-11.17M
P/E Ratio:
-2.8152
EPS:
-0.3161
Net Cash Flow:
$-10.98M
1W Performance:
+7.07%
1M Performance:
-4.51%
6M Performance:
-7.86%
1Y Performance:
-13.60%
1-Day Range:
$0.8898
$0.9525
1-Week Range:
$0.842
$0.9525
52-Week Range:
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.8899 | 41.82M | 1.12M | -11.17M | -10.98M | -0.3161 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Renovorx Inc Stock (RNXT) Latest News
Is RenovoRx (RNXT) stock creating a trading range | RenovoRx beats EPS by 2%, posts narrower Q4 lossBond Issuance - Newser
RenovoRx (RNXT) 2026 proxy: board elections, equity pool increase and auditor vote - Stock Titan
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET - Investing News Network
What RenovoRx plans to cover on its May 14 results call - Stock Titan
JonesTrading Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
[EFFECT] RenovoRx, Inc. SEC Filing - Stock Titan
RenovoRx (RNXT) registers 15.96M resale shares; warrants carry $1.75–$1.93 strikes - Stock Titan
[SCHEDULE 13G/A] RenovoRx, Inc. Amended Passive Investment Disclosure - Stock Titan
RenovoRx (RNXT) price target increased by 18.52% to 8.16 - MSN
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - Investing News Network
RenovoRx pancreatic cancer study tests more targeted chemo delivery - Stock Titan
RenovoRx (RNXT) price target decreased by 15.63% to 6.88 - MSN
RNXT (RenovoRx Inc.) narrowly tops Q4 2025 EPS estimates, falls slightly in immediate post-earnings trading.Expert Momentum Signals - Cổng thông tin điện tử Tỉnh Sơn La
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial - TipRanks
RenovoRx (RNXT) registers 15.9M resale shares including warrants (S-3) - Stock Titan
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - marketscreener.com
RenovoRx Inc Presents Clinical Data Supporting Targeted Chemotherapeutic Delivery Via Tamp Therapy Platform - marketscreener.com
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - The Manila Times
Pancreatic cancer scans show early response after artery-delivered chemo - Stock Titan
Fund Flows: Is RenovoRx Inc exposed to political risk2026 Trading Volume Trends & Real-Time Sentiment Analysis - baoquankhu1.vn
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET - ADVFN
Meme Stocks: Is RenovoRx Inc a defensive stockWeekly Trade Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - ADVFN
Signal Recap: Whats the outlook for RenovoRx Incs sector2026 Sector Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
What is the short interest in RenovoRx (RNXT) Stock | Price at $0.97, Up 3.41%Stock Screening - Newser
RenovoRx receives Japanese patent for RenovoCath device By Investing.com - Investing.com Australia
RNXT: HC Wainwright Reiterates Buy Rating and $3.00 Price Target - GuruFocus
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - Bitget
RenovoRx receives Japanese patent for RenovoCath device - Investing.com
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - Investing News Network
Cancer drug-delivery device wins Japan patent allowance as RenovoRx expands - Stock Titan
RenovoRx (RNXT) CCO awarded 128,550 options at $0.98 exercise price - Stock Titan
RenovoRx (RNXT) CMO granted 621,727 options vesting through 2030 - Stock Titan
Stock Recap: How does RenovoRx Inc perform in inflationary periods2026 Historical Comparison & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will RenovoRx (RNXT) Stock Hit New Highs | Price at $0.93, Down 4.90%Community Driven Stock Picks - Newser
RenovoRx, Inc. Appoints Ramtin Agah, M.D. As Executive Chairman , Effective February 27, 2026 - marketscreener.com
RNXT Stock Analysis: RenovoRx Inc. biotech trades near 1 dollar on mild daily gain - Newser
RNXT Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Taiwan News
Street Watch: How does RenovoRx Inc perform in inflationary periods2026 Price Action Summary & Reliable Price Breakout Signals - baoquankhu1.vn
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - Investing News Network
RNXT SEC FilingsRenovorx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
RenovoRx Reports Solid First Full Year of RenovoCath Commercialization - National Today
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Trade Recap: What chart patterns are forming on RenovoRx IncMarket Performance Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Published on: 2026-03-31 14:32:17 - baoquankhu1.vn
RNXT: 2026 revenue is projected to triple as commercial site expansion accelerates and funding strengthens - TradingView
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):